Evolution of Coronavirus Disease 2019 (COVID-19) Patients in Extremadura

To determine the effectiveness of each drug the investigators will use the percentage of deceased subjects who were treated with each one of them.

To determine the effectiveness of each drug the investigators will use the time in days from the start to the pharmacological treatment to death.

To determine the effectiveness of each drug the investigators will use the time from the start of the pharmacological treatment to recovery, understanding as recovery the disappearance of symptoms and two negative reverse transcription polymerase chain reaction (PCR) separated by at least 24 hours.

The investigators will analyze the effect of the age in years of the hospitalized patients on the effectiveness of the pharmacological treatments assessed in terms of mortality.

The investigators will analyze the effect of the gender (male or female) of the hospitalized patients on the effectiveness of the pharmacological treatments assessed in terms of mortality.

The investigators will analyze the effect of the presence of arterial hypertension (yes or not) on the effectiveness of the pharmacological treatments in hospitalized patients assessed in terms of mortality.

We will analyze the effect of the presence of diabetes (yes or not) on the effectiveness of the pharmacological treatments in hospitalized patients assessed in terms of mortality.

The investigators will analyze the effect of the presence of dyslipidemia (yes or not) on the effectiveness of the pharmacological treatments in hospitalized patients assessed in terms of mortality.

The investigators will analyze the effect of the presence of a history of myocardial infarction (yes or not) on the effectiveness of the pharmacological treatments in hospitalized patients assessed in terms of mortality.

The investigators will analyze the effect of the presence of a history of angina (yes or not) on the effectiveness of the pharmacological treatments in hospitalized patients assessed in terms of mortality.

The investigators will analyze the effect of the presence of a history of chronic heart failure (yes or not) on the effectiveness of the pharmacological treatments in hospitalized patients assessed in terms of mortality.

The investigators will analyze the effect of the presence of a history of peripheral arterial disease (yes or not) on the effectiveness of the pharmacological treatments in hospitalized patients assessed in terms of mortality.

The investigators will analyze the effect of the presence of a history of ictus (yes or not) on the effectiveness of the pharmacological treatments in hospitalized patients assessed in terms of mortality.

The investigators will analyze the effect of the presence of a history of dementia (yes or not) on the effectiveness of the pharmacological treatments in hospitalized patients assessed in terms of mortality.

The investigators will analyze the effect of the presence of a history of neuromuscular disease (yes or not) on the effectiveness of the pharmacological treatments in hospitalized patients assessed in terms of mortality.

The investigators will analyze the effect of the presence of a history of chronic obstructive pulmonary disease (yes or not) on the effectiveness of the pharmacological treatments in hospitalized patients assessed in terms of mortality.

The investigators will analyze the effect of the presence of a history of asthma (yes or not) on the effectiveness of the pharmacological treatments in hospitalized patients assessed in terms of mortality.

The investigators will analyze the effect of the presence of a history of chronic kidney disease (yes or not) on the effectiveness of the pharmacological treatments in hospitalized patients assessed in terms of mortality.

To determine the severity of the disease, the investigators will use the following severity classification:

Uncomplicated disease (symptoms of the upper respiratory tract with or without nonspecific symptoms: fever, muscle pain or atypical symptoms in the elderly), mild pneumonia (pneumonia confirmed on chest radiography and without signs of severity, with room air oxygen saturation > 90% and CURB65 score* ≤ 1), severe pneumonia (failure of > 1 organ or air ambient oxygen saturation < 90% or respiratory rate ≥ 30 rpm), respiratory distress (clinical findings, bilateral infiltrates on chest radiography and oxygenation deficit with PaO2 / FiO2 ≤ 300 mmHg), sepsis (organic dysfunction that can be identified as an acute change in the SOFA score > 2 points) and septic shock (arterial hypotension that persists after administration of resuscitation volume and that requires vasopressors to maintain a mean arterial pressure ≥ 65 mmHg and lactate ≥ 2 mmol / L in the absence of hypovolemia).

The investigators will analyze the effect of usual taking non-steroidal anti-inflammatory drugs (yes or not) on the effectiveness of the pharmacological treatments for SARS-Cov2 in hospitalized patients assessed in terms of mortality.

The investigators will analyze the effect of usual taking angiotensin II receptor antagonists (yes or not) on the effectiveness of the pharmacological treatments for SARS-Cov2 in hospitalized patients assessed in terms of mortality.

The investigators will analyze the effect of usual taking oral anti-diabetics drugs (yes or not) on the effectiveness of the pharmacological treatments for SARS-Cov2 in hospitalized patients assessed in terms of mortality.

The investigators will analyze the effect of usual administration of insulin (yes or not) on the effectiveness of the pharmacological treatments for SARS-Cov2 in hospitalized patients assessed in terms of mortality.

The investigators will collect the dosage of each drug used in clinical practice (amount of drug administered, usually in milligrams, per time interval in hours)

The investigators will collect the days of use of each drug.

The investigators will collect any side effect, the suspected causative drug, start and end data of the side effect, if it is severe or not and the outcome (full recovery, recovery with sequelae or death).

The investigators will use the hospitalization days of the patients treated with each drug used for the treatment of SARS-Cov2.

The investigators will analyze the percentage of patients treated with each drug that need admission to the intensive care unit and the mean number of days that they remained in that unit.

To determine the maximum level of severity reached, the investigators will use the following classification:

Uncomplicated disease (symptoms of the upper respiratory tract with or without nonspecific symptoms), mild pneumonia (confirmed on chest radiography and without signs of severity, with room air oxygen saturation > 90% and Pneumonia Severity Score (CURB65) ≤ 1), severe pneumonia (failure of > 1 organ or air ambient oxygen saturation < 90% or respiratory rate ≥ 30 rpm), respiratory distress (bilateral infiltrates on chest radiography and oxygenation deficit with partial pressure of oxygen / inspiratory oxygen fraction ≤ 300 mmHg), sepsis (organic dysfunction with an acute change in the Sequential Organ Failure Assessment Score > 2 points) and septic shock (arterial hypotension that persists after administration of resuscitation volume and that requires vasopressors to maintain a mean arterial pressure ≥ 65 mmHg and lactate ≥ 2 mmol / L in the absence of hypovolemia)

To determine the evolution of this group of patient the investigators will use the need admission on the intensive care unit or respiratory intermediate care unit, the need of ventilatory support (conventional oxygen therapy, high-flow oxygen therapy, invasive or non-invasive ventilation, prone position, extracorporeal membrane oxygenation), recovery or death and medical complications during admission (other infections, severe arrhythmia, respiratory distress, kidney failure, heart failure, myocardial infarction, angina, auricular fibrillation / flutter, stroke and others).

The investigators will collect the presence of the main symptoms on admission: fever, shaking chills, cough, expectoration, hemoptysis, dyspnea, chest pain, headache, diarrhea, asthenia, anorexia, malaise, anosmia, dysgeusia, nasal obstruction, rhinorrhea, odynophagia, myalgia or body pain, weight loss, nausea and vomiting

The investigators will collect the temperature in degrees centigrade on admission and every seven days during admission

The investigators will collect the heart rate in beats per minute on admission and every seven days during admission.

The investigators will collect the oxygen saturation breathing ambient air by arterial blood gases or pulse oximetry, depending on availability, on admission and every seven days during admission.

The investigators will collect the blood pressure in millimeters of mercury on admission and every seven days during admission.

The investigators will collect the presence of the main symptoms during the follow-up: fever, shaking chills, cough, expectoration, hemoptysis, dyspnea, chest pain, headache, diarrhea, asthenia, anorexia, malaise, anosmia, dysgeusia, nasal obstruction, rhinorrhea, odynophagia, myalgia or body pain, weight loss, nausea and vomiting on diagnosis and every seven days during de follow up.

The investigators will collect the temperature in degrees centigrade at diagnosis.

The investigators will collect the heart rate in beats per minute at diagnosis.

The investigators will collect the respiratory rate in breaths per minute at diagnosis

The investigators will collect the oxygen saturation breathing ambient air by arterial blood gases or pulse oximetry, depending on availability, at diagnosis.

The investigators will collect the blood pressure in millimeters of mercury at diagnosis.

The investigators will collect the radiological findings of the chest radiograph and the computed tomography (CT) according to two classifications:

Unilateral or bilateral alveolar infiltrate, diffuse intersticial infiltrate, pattern on ground glass, pleural effusion and normal.

Intersticial infiltrate, lobar or bilobar alveolar infiltrate, unilateral or bilateral alveolar lung infiltrate with three degrees of severity (mild, moderate or severe with <25%, 25-50% or >50% of lung affected, respectively), pleural effusion and normal.

These findings will be collected weekly during admission to the conventional ward and daily during admission to intensive or intermediate respiratory care unit.

The investigators will collect the radiological findings of the chest radiograph and the computed tomography (CT) according to two classifications:

Unilateral or bilateral alveolar infiltrate, diffuse intersticial infiltrate, pattern on ground glass, pleural effusion and normal.

Intersticial infiltrate, lobar or bilobar alveolar infiltrate, unilateral or bilateral alveolar lung infiltrate with three degrees of severity (mild, moderate or severe with <25%, 25-50% or >50% of lung affected, respectively), pleural effusion and normal.

These findings will be collected at diagnosis.

The investigators will collect the ferritin levels in nanogram per milliliter, weekly during admission to the conventional ward and daily during admission to intensive or intermediate respiratory care unit.

The investigators will collect the D-dimer levels in nanogram per milliliter, weekly during admission to the conventional ward and daily during admission to intensive or intermediate respiratory care unit.

The investigators will collect the interleukin 6 levels in picogram per milliliter, weekly during admission to the conventional ward and daily during admission to intensive or intermediate respiratory care unit

The investigators will collect the lymphocyte count expressed in 10*3 per milliliter, weekly during admission to the conventional ward and daily during admission to intensive or intermediate respiratory care unit

The investigators will collect the c-reactive protein level in milligrams per deciliters, weekly during admission to the conventional ward and daily during admission to intensive or intermediate respiratory care unit.

The investigators will collect the result (positive or negative) of all tests performed to confirm the diagnosis of SARS-CoV2 infection: polymerase chain reaction test, serological test and antigen detection test.

The investigators will collect the ferritin levels in nanogram per milliliter at diagnosis.

The investigators will collect the D-dimer levels in nanogram per milliliter at diangosis.

The investigators will collect the interleukin 6 levels in picogram per milliliter at diagnosis.

The investigators will collect the lymphocyte count expressed in 10*3 per milliliter diagnosis.

The investigators will collect the c-reactive protein level in milligrams per deciliters at diagnosis.

The investigators will collect the result (positive or negative) of all tests performed to confirm the diagnosis of SARS-CoV2 infection: polymerase chain reaction test, serological test and antigen detection test.

To determine the quality of life related to health the investigators will use the Short Form-12 Health Survey after recovery. This questionnaire assesses the degree of well-being and functional capacity and it is composed of twelve items and eight dimensions (physical function, physical role, body pain, mental health, general health, vitality, social function and emotional role), defining a positive or negative state of the physical and mental health. Some included items are: "In general, would you say that your health is", "During the last 4 weeks, to what extent has your physical health or emotional problems hindered your usual social activities with family, friends, neighbors or other people? "," Did you have pain in any part of your body during the last 4 weeks? ". The response options form Likert-type scales where the number of options varies from three to six points. The score ranges from 0 to 100. A higher score implies a better health-related quality of life.